Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

Tobias Boch, MD, Thomas Luft, MD PhD, Maximilian Mossner, Johann-Christoph Jann, Daniel Nowak, MD, Christine Folz, Jennifer Klemmer, Susanne Brendel, Harald Fricke, MD, Claudia Kunz, PhD, Wolf-Karsten Hofmann, MD, Florian Nolte, MD

Blood (2016) 128 (22): 228.

https://doi.org/10.1182/blood.V128.22.228.228

Published: 2016

Journal Articles

The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study

Evi launiger-Lörsch, Thomas Luft, Stephanie Fey, Julia Obländer, Susanne Brendel, Jovita Pressler, Johann-Christoph Jann, Claudia Kunz, Anthony D. Ho, Harald Fricke, Maximilian Mossner, Georgia Metzgeroth, Daniel Nowak, Wolf-Karsten Hofmann, Florian Nolte

Blood (2014) 124 (21): 4669.

https://doi.org/10.1182/blood.V124.21.4669.4669

Published: 2014

Journal Articles

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Florian Nolte, MD, Claudia Kunz, Stephanie Fey, Julia Obländer, Susanne Brendel, Marion Klaumünzer, Maximilian Mossner, Johann-Christoph Jann, Stefanie Uhlig, Daniel Nowak, MD, Harald Fricke, MD, Wolf-Karsten Hofmann, MD

Blood (2013) 122 (21): 1562.

https://doi.org/10.1182/blood.V122.21.1562.1562

Published: 2013

Journal Articles

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions

Natalie Hartmann, Joanna J. Messmann, Frank Leithäuser, Maxi Weiswange, Michael Kluge, Harald Fricke, Klaus-Michael Debatin, Gudrun Strauss

Blood (2013) 121 (3): 556–565.

https://doi.org/10.1182/blood-2012-04-423392

Published: 2013

Includes: Supplemental data

Journal Articles

APG101 - a Novel Inhibitor of CD95/CD95L Signaling Prevents Graft-Versus-Host Disease without Disabling T Cell Effector Function and Anti-Tumor Activity,

Gudrun Strauss, PhD, Natalie Hartmann, PhD, Michael Kluge, PhD, Harald Fricke, MD, PhD, Klaus-Michael Debatin, MD, PhD

Blood (2011) 118 (21): 4019.

https://doi.org/10.1182/blood.V118.21.4019.4019

Published: 2011

NARROW

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions

APG101 - a Novel Inhibitor of CD95/CD95L Signaling Prevents Graft-Versus-Host Disease without Disabling T Cell Effector Function and Anti-Tumor Activity,

Email alerts

ASH Publications

American Society of Hematology

Safety and Efficacy of the CD95-Ligand Inhibitor APG101 in Transfusion-Dependent Patients with Low Risk MDS: Results from a Phase I Study

The Fas Ligand Inhibitor APG101 in Transfusion Dependent Patients with Low Risk MDS: Interim Results from a Phase I Study

The New CD95 Ligand Inhibitor APG101 Leads To Decreased Apoptosis and Improved Erythroid Differentiation In Primary CD34+ Cells From Patients With Low Risk Myelodysplastic Syndrome (MDS)

Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions

APG101 - a Novel Inhibitor of CD95/CD95L Signaling Prevents Graft-Versus-Host Disease without Disabling T Cell Effector Function and Anti-Tumor Activity,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only